Trials for discovering an anti-malarial drug, which can compete Schistosomal infection in
co-endemic areas, are ongoing. Some preliminary studies were done on Synriam (SYN), antimalarial
drug combination (arterolane maleate and piperaquine phosphate) released from
Ranbaxy, to test its anti-schistosomal effect. But, in vitro incubation of SYN with different
Schistosoma haematobium stages was not fully assessed. This study determined the antischistosomal
in vitro effect of SYN on adult and juvenile stages of Schistosoma haematobium-
Egyptian strain. Adult and juvenile worms were incubated with ascending concentrations of
SYN and with praziquantel as positive control. Viability, survival, morphological and ultrastructural
changes were assessed at different time points. Higher concentrations of 60, 80
μg/ml showed rapid and lethal effects on adult and juvenile stages of both species, with prominent
ultrastructural alterations. Concentrations of (10, 20, & 40μg/ml) showed mild to moderate
effect on adult schistosomes. On contrarily to praziquantel, larval immature stages responded
significantly and rapidly to low concentration of SYN with 100% death rate. The present
findings were consistent with the evaluation of anti-schistosomal therapeutic effect of SYN to
be utilized in malaria co-endemic areas.